Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tyrosinase precursor | 0.0104 | 0.5 | 0.5 |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0104 | 0.5 | 0.5 |
Loa Loa (eye worm) | ShTK domain-containing protein | 0.0104 | 0.5 | 0.5 |
Loa Loa (eye worm) | tyrosinase 1 | 0.0104 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0104 | 0.5 | 0.5 | |
Brugia malayi | Common central domain of tyrosinase family protein | 0.0104 | 0.5 | 0.5 |
Brugia malayi | Hypothetical tyrosinase-like protein F21C3.2 in chromosome I | 0.0104 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0104 | 0.5 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0104 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0104 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0104 | 0.5 | 0.5 | |
Onchocerca volvulus | 0.0104 | 0.5 | 0.5 | |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0104 | 0.5 | 0.5 |
Loa Loa (eye worm) | ShTK domain-containing protein | 0.0104 | 0.5 | 0.5 |
Schistosoma mansoni | tyrosinase precursor | 0.0104 | 0.5 | 0.5 |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0104 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
(functional) | > 10.495 ug/ml | In vitro cytotoxicity evaluation on human fibroblasts measured by fluorescence after 72h | WHO/TDR. | No reference |
% motility reduction (functional) | = 0 % | Motility reduction assay in Schistosoma mansoni Puerto Rican adult worms | WHO/TDR. | No reference |
% motility reduction (functional) | = 0 % | Motility reduction assay in Onchocerca ochengi adult worms | WHO/TDR. | No reference |
% motility reduction (functional) | = 100 % | Motility reduction assay in Onchocerca ochengi microfilariae | WHO/TDR. | No reference |
IC50 (functional) | = 3.719 ug/ml | In vitro activity against Trypanosoma brucei measured by florescence after 24h | WHO/TDR. | No reference |
IC50 (functional) | 3.719 ug/ml | WHO-TDR: Human African Trypanosomiasis (HAT) | ChEMBL. | No reference |
IC50 (functional) | > 10.495 ug/ml | In vitro activity against Plasmodium falciparum measured by colorimetry after 72h | WHO/TDR. | No reference |
IC50 (functional) | > 10.495 ug/ml | In vitro activity against Trypanosoma cruzi in human lung fibroblast measured by colorimetry after 7 days | WHO/TDR. | No reference |
IC50 (functional) | > 10.495 ug/ml | In vitro activity against Leishmania infantum in mouse macrophages measured by cell viability after 5 days | WHO/TDR. | No reference |
IC50 | > 10.495 ug/ml | WHO-TDR: Cytotoxicity | ChEMBL. | No reference |
IC50 (functional) | > 10.495 ug/ml | WHO-TDR: Chagas disease | ChEMBL. | No reference |
IC50 (functional) | > 10.495 ug/ml | WHO-TDR: Leishmaniasis | ChEMBL. | No reference |
IC50 (functional) | > 10.495 ug/ml | WHO-TDR: Malaria | ChEMBL. | No reference |
Inhibition (functional) | = 0 % | WHO-TDR: Schistosomiasis | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | |||
Trypanosoma cruzi | ChEMBL23 | ||
Leishmania infantum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 | ||
Trypanosoma brucei gambiense |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.